Literature DB >> 2913928

Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients.

E W Willoughby1, E Grochowski, D K Li, J Oger, L F Kastrukoff, D W Paty.   

Abstract

A prospective study of serial magnetic resonance (MR) scans of the brain was carried out every 2 weeks for 4 to 6 months in 9 patients with mild, clinically definite, relapsing/remitting multiple sclerosis (MS). Six of the 9 patients developed a total of 12 asymptomatic new lesions in various parts of the brain. In none of the patients were the changes on MR scan accompanied by relevant new neurological symptoms or signs. New MR lesions had a characteristic temporal profile, reaching a maximum size in approximately 4 weeks before gradually shrinking, usually leaving a small residual abnormality indistinguishable from chronic MS lesions. The frequent occurrence of new asymptomatic lesions indicates that MS may be a more active process even in mildly affected asymptomatic patients than has been previously realized. The results emphasize the potential importance of using MR scanning to measure disease activity in laboratory studies of MS and in the assessment of treatment, particularly in asymptomatic patients in the early stages. We suggest that the expanding and contracting new lesions are the basic or primary lesion in MS, that the characteristic demyelinated plaque is represented by the small residual area that these lesions shrink down to, and that the typical collection of scattered white matter lesions in chronic MS may represent the accumulated residua of dozens or more of these active lesions occurring over many years.

Entities:  

Mesh:

Year:  1989        PMID: 2913928     DOI: 10.1002/ana.410250107

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  41 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Primary central nervous system lymphoma imitates multiple sclerosis.

Authors:  L M DeAngelis
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

Review 4.  The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system.

Authors:  W I McDonald; D Barnes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

5.  Vertical gaze palsy due to a resolving midbrain lesion.

Authors:  P Trend; B D Youl; M D Sanders; R S Kocen; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

6.  Pure-tone auditory thresholds are not chronically elevated in multiple sclerosis.

Authors:  Richard L Doty; Isabelle Tourbier; Sherrie Davis; Jennifer Rotz; Jennifer L Cuzzocreo; Jonathan Treem; Neil Shephard; Dzung L Pham
Journal:  Behav Neurosci       Date:  2012-02-06       Impact factor: 1.912

7.  Impact of cervical stenosis on multiple sclerosis lesion distribution in the spinal cord.

Authors:  Daniel Gratch; David Do; Pouya Khankhanian; Matthew Schindler; J Eric Schmitt; Joseph R Berger
Journal:  Mult Scler Relat Disord       Date:  2020-07-20       Impact factor: 4.339

8.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.